StockData
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. (SCNI) company profile

SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.01 (-1.40%)

Close on Nov 18, 2026Market cap $1.27MP/E –Yield –

About Scinai Immunotherapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company that operates two distinct business segments: a contract development and manufacturing organization (CDMO) and an in-house research and development unit. The CDMO business unit provides biopharmaceutical development and manufacturing services to external clients. Meanwhile, the R&D segment focuses on advancing biological therapeutics for inflammation and immunology conditions, primarily through a pipeline of nanosized VHH antibody fragments. Its therapeutic development efforts include targeting Interleukin-17 for autoimmune diseases such as plaque psoriasis and psoriatic arthritis, as well as an optioned monoclonal antibody candidate targeting soluble Fas ligand.

The company operates manufacturing and development facilities in Jerusalem and Yavne, Israel. Its principal executive offices and corporate headquarters are located at the Jerusalem BioPark on the Hadassah Ein Kerem Campus in Jerusalem, Israel. Additionally, the company conducts activities internationally through a wholly owned subsidiary in Poland.

Summary of the business section of Scinai Immunotherapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Scinai Immunotherapeutics Ltd.
Headquarters
Jerusalem, L3
Address
Jerusalem Biopark, 2nd Floor, Hadassah Ein Kerem Campus 00000
Phone
972-8-9302529
Website
scinai.com
Employees
45, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Ziv Haft, Tel-Aviv,Israel

Stock & identifiers

Ticker
SCNI
Former tickers
BVXV until May 15, 2024
Exchange
Nasdaq
IPO date
May 13, 2015
Shares outstanding
13.87B, Dec 31, 2025
Public float
$16.70M, Jun 30, 2022
Filer category
Non-accelerated filer
Stock splits
1-for-10 reverse, Aug 21, 2026; 1-for-10 reverse, May 21, 2024; 1-for-10 reverse, Nov 25, 2022
SEC CIK
1611747
CUSIP
09073Q203
ISIN
US09073Q2031
FIGI
BBG007TGL1R2
Share class FIGI
BBG007TGL3Q9
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Amir ReichmanChief Executive Officer, Director711,637,600
Elad MarkChief Operating Officer160,355,016
Mark GermainDirector120,000,000
Yael MargolinDirector66,800
Uri Ben-OrDirector33,329,004
Samuel J. MoedDirector–
Adi RavivDirector66,800
Jay GreenDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 13, 2015
Offer price
$5.00
Securities offered
1,910,000
Gross proceeds
$9.55M
Exchange
Nasdaq
First trading day
May 11, 2015
First-day close
$5.000.0%
Lock-up ends (est.)
Nov 7, 2015

“40 Ordinary Shares Warrants to Purchase 1,910,000 American Depositary Shares We are offering 1,910,000 American Depositary Shares, or ADSs, and warrants to purchase 1,910,000 ADSs, or warrants, at an offering price of $5.00 per ADS and $ 0.01 per warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“45 employees, 41 of whom were employed in the CDMO subsidiary company and 4 of whom were employed in research and development.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 29, 2025Late filingNotification of late filing
Apr 30, 2024Late filingNotification of late filing
Aug 28, 2023Name changeName changed from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd.
May 4, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 3, 2023Late filingNotification of late filing
Apr 29, 2021Late filingNotification of late filing
May 13, 2020DelistingNotice of delisting from exchange (Form 25)
May 13, 2015IPOInitial public offering priced (424B4 prospectus)
Apr 20, 2015ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?